Arc Nouvel News | Biotech & Pharma Regulatory Insights

14 Apr

Articles
No Comments

What It Takes to Lead at the Top: Dr. Roy Baynes and the Discipline of Meaningful Medicine

There is one idea that seems to sit at the center of Dr. Roy Baynes’s career, and perhaps at the center of his leadership philosophy too: important work must remain anchored to human benefit. In an era that can sometimes...

06 Apr

Articles
No Comments

Precision Medicine Through the Patient Lens: The Wondrlink Impact

Precision medicine is reshaping oncology by shifting treatment selection from histology alone to the molecular architecture of each patient’s tumor. Platforms designed to identify actionable somatic biomarkers now match patients to targeted therapies based on genomic alterations, receptor expression, and...

02 Apr

Articles
No Comments

Oncology Trial Recruitment in the Age of AI: Strategic Insights for Clinical Development Leaders

Over the past decade, oncology drug development has undergone a profound scientific transformation. Biomarker-driven therapies, adaptive designs, and tissue-agnostic indications have expanded what is clinically possible. Yet the operational engine of clinical trials, patient identification and enrollment, has not evolved...

26 Mar

Articles
No Comments

AI-Generated Control Arms in Clinical Trials: Evidence, Opportunities, and Strategic Considerations

Clinical trials are undergoing structural change. As therapies become more targeted and patient populations more fragmented, the traditional randomized controlled trial (RCT) is increasingly difficult to execute. This is particularly true in oncology, rare diseases, and precision medicine, where eligible...

20 Mar

Articles
No Comments

What It Takes to Lead at the Top: Jill DeSimone on Purpose, Trust, and the Human Side of Pharma Leadership

In every industry, there are executives who build impressive careers. And then there are leaders whose careers become a study in impact: not only in terms of business performance, but in the lives they shape, the standards they set, and...

03 Mar

Articles
No Comments

FDA Project Optimus: The “Right Dose” in Oncology Drug Development

Oncology drug development is undergoing a fundamental methodological transformation. With the launch of Project Optimus in 2021, the U.S. Food and Drug Administration (FDA) formally signaled that the historical paradigm centered on identifying the maximum tolerated dose (MTD) is no...

26 Feb

Articles
No Comments

Who is Arc Nouvel: Dr. Vivian Li on Strategy, Risk, and Value in Clinical Development

Across the drug development lifecycle, including pre-IND readiness, early clinical transitions, manufacturing evolution, and regulatory engagement, biotech and pharmaceutical companies turn to Arc Nouvel for specialized guidance. In oncology and beyond, the firm’s clients are often navigating early clinical decisions...

26 Feb

Articles
No Comments

Who is Arc Nouvel: Dr. Robert Charnas on Regulatory Strategy, Patient-Focused Development, and the Discipline to Stop

Arc Nouvel is a boutique consulting firm that supports pharmaceutical, biotechnology, and investment clients with end-to-end clinical development solutions, strategic consulting, operational support, and executive coaching across early- to late-phase programs. But the firm’s real advantage lies in the experience...

24 Feb

Articles
No Comments

Who Is Arc Nouvel? A Conversation with Dr. Gavin Liu on Cell Therapy CMC Strategy and GMP Manufacturing

Arc Nouvel works with biotechnology and pharmaceutical companies at inflection points, pre-IND preparation, early clinical transitions, manufacturing evolution, and regulatory engagement. At these moments, scientific promise alone is not enough. What determines whether a therapy advances efficiently or stalls under...

17 Feb

Articles
No Comments

Rethinking the “Dark Side” With Dr. Ildikó Csíki

For decades, medicine has told itself a story. It is a story with moral clarity: white coats and academic halls represent purity of purpose, while industry, pharmaceutical companies, biotech startups, commercialization offices, lurks somewhere in the shadows, necessary but suspect....

News

What It Takes to Lead at the Top: Dr. Roy Baynes and the Discipline of Meaningful Medicine

Precision Medicine Through the Patient Lens: The Wondrlink Impact

Oncology Trial Recruitment in the Age of AI: Strategic Insights for Clinical Development Leaders

AI-Generated Control Arms in Clinical Trials: Evidence, Opportunities, and Strategic Considerations

What It Takes to Lead at the Top: Jill DeSimone on Purpose, Trust, and the Human Side of Pharma Leadership

FDA Project Optimus: The “Right Dose” in Oncology Drug Development

Who is Arc Nouvel: Dr. Vivian Li on Strategy, Risk, and Value in Clinical Development

Who is Arc Nouvel: Dr. Robert Charnas on Regulatory Strategy, Patient-Focused Development, and the Discipline to Stop

Who Is Arc Nouvel? A Conversation with Dr. Gavin Liu on Cell Therapy CMC Strategy and GMP Manufacturing

Rethinking the “Dark Side” With Dr. Ildikó Csíki

Contact us Now

Menu

Contact Us

Follow Us